Womb cancer breakthrough as new drug gives hope

Sign up for the Independent Women email for the latest news, opinion and features Get the Independent Women email for free Get the Independent Women email for free SIGN UP I would like to be emailed about offers, events and updates from The Independent. Read our privacy policy A drug that could buy women with womb cancer more time with their loved ones before the disease progresses is to be made available on the NHS. Professor Peter Clark, NHS England’s Cancer Drugs Fund lead, said: “The rollout of this drug as a first-line treatment on the NHS is great news for patients living with this type of womb cancer – this new immunotherapy could offer hundreds of women the hope of precious extra time to live well before their cancer progresses.” According to Nice, there are two main types of womb cancer – endometrial cancer and uterine sarcoma – with about 9,000 new cases every year in the UK. Helen Knight, director of medicines evaluation at Nice, said: “Advanced or recurrent womb cancer has a devastating effect on quality of life and there are limited treatment options available. “We are focused on delivering what matters most and getting care to those who need it fast, so I am delighted this treatment option will be made quickly available through the CDF, enabling people with this type of cancer to enjoy more precious time with their families and loved ones.” Jemperli is administered using a 30-minute drip in hospital every three weeks alongside chemotherapy for six cycles.